Phenotypic subgrouping and multi-omics analyses reveal reduced diazepam-binding inhibitor (DBI) protein levels in autism spectrum disorder with severe language impairment.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
04
2018
accepted:
08
03
2019
entrez:
29
3
2019
pubmed:
29
3
2019
medline:
18
12
2019
Statut:
epublish
Résumé
The mechanisms underlying autism spectrum disorder (ASD) remain unclear, and clinical biomarkers are not yet available for ASD. Differences in dysregulated proteins in ASD have shown little reproducibility, which is partly due to ASD heterogeneity. Recent studies have demonstrated that subgrouping ASD cases based on clinical phenotypes is useful for identifying candidate genes that are dysregulated in ASD subgroups. However, this strategy has not been employed in proteome profiling analyses to identify ASD biomarker proteins for specific subgroups. We therefore conducted a cluster analysis of the Autism Diagnostic Interview-Revised (ADI-R) scores from 85 individuals with ASD to predict subgroups and subsequently identified dysregulated genes by reanalyzing the transcriptome profiles of individuals with ASD and unaffected individuals. Proteome profiling of lymphoblastoid cell lines from these individuals was performed via 2D-gel electrophoresis, and then mass spectrometry. Disrupted proteins were identified and compared to the dysregulated transcripts and reported dysregulated proteins from previous proteome studies. Biological functions were predicted using the Ingenuity Pathway Analysis (IPA) program. Selected proteins were also analyzed by Western blotting. The cluster analysis of ADI-R data revealed four ASD subgroups, including ASD with severe language impairment, and transcriptome profiling identified dysregulated genes in each subgroup. Screening via proteome analysis revealed 82 altered proteins in the ASD subgroup with severe language impairment. Eighteen of these proteins were further identified by nano-LC-MS/MS. Among these proteins, fourteen were predicted by IPA to be associated with neurological functions and inflammation. Among these proteins, diazepam-binding inhibitor (DBI) protein was confirmed by Western blot analysis to be expressed at significantly decreased levels in the ASD subgroup with severe language impairment, and the DBI expression levels were correlated with the scores of several ADI-R items. By subgrouping individuals with ASD based on clinical phenotypes, and then performing an integrated transcriptome-proteome analysis, we identified DBI as a novel candidate protein for ASD with severe language impairment. The mechanisms of this protein and its potential use as an ASD biomarker warrant further study.
Sections du résumé
BACKGROUND
The mechanisms underlying autism spectrum disorder (ASD) remain unclear, and clinical biomarkers are not yet available for ASD. Differences in dysregulated proteins in ASD have shown little reproducibility, which is partly due to ASD heterogeneity. Recent studies have demonstrated that subgrouping ASD cases based on clinical phenotypes is useful for identifying candidate genes that are dysregulated in ASD subgroups. However, this strategy has not been employed in proteome profiling analyses to identify ASD biomarker proteins for specific subgroups.
METHODS
We therefore conducted a cluster analysis of the Autism Diagnostic Interview-Revised (ADI-R) scores from 85 individuals with ASD to predict subgroups and subsequently identified dysregulated genes by reanalyzing the transcriptome profiles of individuals with ASD and unaffected individuals. Proteome profiling of lymphoblastoid cell lines from these individuals was performed via 2D-gel electrophoresis, and then mass spectrometry. Disrupted proteins were identified and compared to the dysregulated transcripts and reported dysregulated proteins from previous proteome studies. Biological functions were predicted using the Ingenuity Pathway Analysis (IPA) program. Selected proteins were also analyzed by Western blotting.
RESULTS
The cluster analysis of ADI-R data revealed four ASD subgroups, including ASD with severe language impairment, and transcriptome profiling identified dysregulated genes in each subgroup. Screening via proteome analysis revealed 82 altered proteins in the ASD subgroup with severe language impairment. Eighteen of these proteins were further identified by nano-LC-MS/MS. Among these proteins, fourteen were predicted by IPA to be associated with neurological functions and inflammation. Among these proteins, diazepam-binding inhibitor (DBI) protein was confirmed by Western blot analysis to be expressed at significantly decreased levels in the ASD subgroup with severe language impairment, and the DBI expression levels were correlated with the scores of several ADI-R items.
CONCLUSIONS
By subgrouping individuals with ASD based on clinical phenotypes, and then performing an integrated transcriptome-proteome analysis, we identified DBI as a novel candidate protein for ASD with severe language impairment. The mechanisms of this protein and its potential use as an ASD biomarker warrant further study.
Identifiants
pubmed: 30921354
doi: 10.1371/journal.pone.0214198
pii: PONE-D-18-11304
pmc: PMC6438570
doi:
Substances chimiques
Biomarkers
0
Diazepam Binding Inhibitor
0
Proteome
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0214198Subventions
Organisme : NIEHS NIH HHS
ID : R21 ES023061
Pays : United States
Organisme : NIEHS NIH HHS
ID : R21 ES028124
Pays : United States
Organisme : NIMH NIH HHS
ID : U24 MH081810
Pays : United States
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Mol Autism. 2013 May 22;4(1):14
pubmed: 23697635
Brain Res Bull. 2003 Oct 15;61(6):557-69
pubmed: 14519452
Biotechniques. 2003 Feb;34(2):374-8
pubmed: 12613259
PLoS One. 2011 Feb 17;6(2):e16715
pubmed: 21379579
Proteomics Clin Appl. 2018 May;12(3):e1700085
pubmed: 29274201
J Neuroinflammation. 2014 Jun 20;11:113
pubmed: 24951035
Mol Psychiatry. 2007 Mar;12(3):292-306
pubmed: 17189958
Mol Autism. 2013 Aug 06;4(1):27
pubmed: 23915542
Mol Autism. 2014 Jul 30;5:41
pubmed: 25126406
Autism Res. 2017 Sep;10(9):1460-1469
pubmed: 28509388
Curr Opin Neurobiol. 2017 Aug;45:178-187
pubmed: 28628841
Horm Behav. 2018 May;101:13-21
pubmed: 29042182
J Proteome Res. 2008 Dec;7(12):5327-32
pubmed: 19367726
Mol Autism. 2018 Apr 16;9:27
pubmed: 29686828
Biol Psychiatry. 2017 Mar 1;81(5):442-451
pubmed: 26392128
J Tradit Complement Med. 2017 Jun 15;7(4):538-552
pubmed: 29034205
Eur Arch Psychiatry Clin Neurosci. 2004 Jun;254(3):143-7
pubmed: 15205966
J Cell Mol Med. 2015 Nov;19(11):2664-78
pubmed: 26290361
Dev Neurobiol. 2013 May;73(5):354-69
pubmed: 23109215
Electrophoresis. 1999 Dec;20(18):3551-67
pubmed: 10612281
Glia. 2018 Jan;66(1):78-93
pubmed: 28925578
Genes Dev. 2014 Mar 1;28(5):479-90
pubmed: 24589777
Am J Hum Genet. 2001 Aug;69(2):463-6
pubmed: 11452364
PLoS One. 2009 Jun 03;4(6):e5775
pubmed: 19492049
Autism Res. 2009 Apr;2(2):78-97
pubmed: 19418574
Nucleic Acids Res. 2012 Jan;40(Database issue):D1016-22
pubmed: 22139918
FASEB J. 2010 Aug;24(8):3036-51
pubmed: 20375269
Trends Genet. 1997 Apr;13(4):163
pubmed: 9097728
Proteomics Clin Appl. 2016 Nov;10(11):1103-1112
pubmed: 27246309
Front Cell Neurosci. 2017 Apr 28;11:120
pubmed: 28503135
Cell Mol Life Sci. 2019 Apr;76(7):1275-1297
pubmed: 30570672
Future Neurol. 2013 Jan 1;8(1):29-42
pubmed: 23637569
Autism Res. 2009 Apr;2(2):67-77
pubmed: 19455643
Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):124-46
pubmed: 22074587
Pharmacogenomics. 2011 Sep;12(9):1235-8
pubmed: 21919600
Dis Markers. 2012;33(5):277-88
pubmed: 22960334
BMC Genomics. 2006 May 18;7:118
pubmed: 16709250
Genes Brain Behav. 2018 Jun;17(5):e12442
pubmed: 29193847
J Child Neurol. 2008 Mar;23(3):307-14
pubmed: 18079313
Mol Autism. 2015 May 13;6:7
pubmed: 26056561
N Am J Med Sci (Boston). 2013;6(3):
pubmed: 24363828
Proc Natl Acad Sci U S A. 1983 Jun;80(11):3531-5
pubmed: 6304714
Mol Autism. 2013 Oct 11;4(1):39
pubmed: 24119295
Clin Proteomics. 2017 Jan 9;14:2
pubmed: 28077936
Nucleic Acids Res. 2011 Jan;39(Database issue):D1005-10
pubmed: 21097893
Eur Psychiatry. 2008 Jun;23(4):289-99
pubmed: 17765485
Pediatr Res. 2011 May;69(5 Pt 2):63R-8R
pubmed: 21289538
Nat Rev Genet. 2017 Jun;18(6):362-376
pubmed: 28260791
J Neurosci. 2006 Jun 28;26(26):6897-906
pubmed: 16807320
Electrophoresis. 2014 Jul;35(14):2046-54
pubmed: 24687421
Neurogenetics. 2008 Jul;9(3):153-61
pubmed: 18563458
Proc Natl Acad Sci U S A. 1988 Sep;85(18):7018-22
pubmed: 3413133
MMWR Surveill Summ. 2018 Apr 27;67(6):1-23
pubmed: 29701730
J Mol Neurosci. 2011 Mar;43(3):443-52
pubmed: 20957522
PLoS One. 2011 Feb 16;6(2):e17116
pubmed: 21359227
JAMA Psychiatry. 2015 Apr;72(4):386-94
pubmed: 25739104
PLoS One. 2013 Jun 26;8(6):e67569
pubmed: 23840741
PLoS One. 2011 Apr 27;6(4):e19067
pubmed: 21556359
Autism Res. 2015 Jun;8(3):338-50
pubmed: 25626423
Mol Psychiatry. 2009 Jun;14(6):590-600
pubmed: 18283277
PLoS One. 2018 Jul 23;13(7):e0201071
pubmed: 30036398
Sci Rep. 2019 Feb 28;9(1):3038
pubmed: 30816183
Genome Med. 2010 Apr 07;2(4):23
pubmed: 20374639
Mol Psychiatry. 2012 Mar;17(3):290-314
pubmed: 21263444
Cell Rep. 2012 Dec 27;2(6):1554-62
pubmed: 23246003
Genomics. 2008 Jan;91(1):22-9
pubmed: 18006270
PLoS One. 2012;7(12):e49475
pubmed: 23227143
Autism Res. 2008 Aug;1(4):240-50
pubmed: 19360674